Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence

Half of heart failure (HF) patients have chronic kidney disease (CKD) complicating their pharmacological management. We evaluated physicians' and patients' patterns of use of evidence‐based medical therapies in HF across CKD stages.

[1]  S. Schneeweiss,et al.  Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population‐based cohort study of >25 000 Medicare beneficiaries , 2022, European journal of heart failure.

[2]  L. Lund,et al.  Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata , 2022, European journal of heart failure.

[3]  S. Pocock,et al.  Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled , 2022, European heart journal.

[4]  L. Lund,et al.  Patient profile and outcomes associated with follow‐up in specialty vs. primary care in heart failure , 2022, ESC heart failure.

[5]  T. N. Harrison,et al.  Management of Adults with Newly Diagnosed Atrial Fibrillation with and without CKD , 2021, Journal of the American Society of Nephrology : JASN.

[6]  Natasha Meunier-McVey,et al.  2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure , 2021, EMJ Cardiology.

[7]  A. Sjölander,et al.  Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care , 2021, European journal of heart failure.

[8]  G. Fonarow,et al.  Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden) , 2021, European journal of heart failure.

[9]  Ravi B. Patel,et al.  Kidney Function and Outcomes in Patients Hospitalized with Heart Failure. , 2021, Journal of the American College of Cardiology.

[10]  Julie A. Wright,et al.  Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease. , 2019, Journal of the American College of Cardiology.

[11]  L. Lund,et al.  Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. , 2019, JACC. Heart failure.

[12]  L. Lund,et al.  The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure , 2018, Upsala journal of medical sciences.

[13]  L. Lund,et al.  Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin–angiotensin–aldosterone system inhibitor use , 2018, European journal of heart failure.

[14]  L. Lund,et al.  Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists , 2018, European journal of heart failure.

[15]  P. Ponikowski,et al.  Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT‐CHF , 2017, European journal of heart failure.

[16]  L. Lund,et al.  Association between enrolment in a heart failure quality registry and subsequent mortality—a nationwide cohort study , 2017, European journal of heart failure.

[17]  P. Rossignol,et al.  Impact of Hyperkalemia and Worsening Renal Function on the Use of Renin Angiotensin Aldosterone System Inhibitors in Chronic Heart Failure With Reduced Ejection Fraction , 2017, Clinical pharmacology and therapeutics.

[18]  J. Carrero,et al.  Systematic underutilisation of secondary preventive drugs in patients with acute coronary syndrome and reduced renal function , 2017, European journal of preventive cardiology.

[19]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[20]  L. Lund,et al.  Prevalence and prognostic impact of kidney disease on heart failure patients , 2016, Open Heart.

[21]  N. Oestreicher,et al.  Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. , 2015, The American journal of managed care.

[22]  L. Räber,et al.  Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. , 2015, European journal of internal medicine.

[23]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[24]  C. O'connor,et al.  Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. , 2014, European heart journal.

[25]  J. McMurray,et al.  SAFETY AND EFFICACY OF EPLERENONE IN PATIENTS AT HIGH RISK FOR HYPERKALEMIA AND/OR WORSENING RENAL FUNCTION. ANALYSES OF THE EMPHASIS-HF STUDY SUBGROUPS (EPLERENONE IN MILD PATIENTS HOSPITALIZATION AND SURVIVAL STUDY IN HEART FAILURE) , 2014 .

[26]  J. McMurray,et al.  Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). , 2013, Journal of the American College of Cardiology.

[27]  T. Mittal,et al.  The ESC Committee for Practice Guidelines (CPG). , 2013, European heart journal.

[28]  Akshay S. Desai,et al.  Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). , 2012, Journal of the American College of Cardiology.

[29]  G. Fonarow,et al.  Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. , 2010, The American journal of cardiology.

[30]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[31]  C. Yancy,et al.  Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study. , 2008, American heart journal.

[32]  G. Fonarow,et al.  High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. , 2007, Journal of cardiac failure.

[33]  Anders Sundström,et al.  The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.

[34]  M. Tonelli,et al.  The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. , 2004, Journal of the American College of Cardiology.

[35]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[36]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[37]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[38]  Ren Johansen.  An Empirical Transition Matrix for Non-homogeneous Markov Chains Based on Censored Observations , 1978 .